Seres Therapeutics has received US Food and Drug Administration (FDA) breakthrough therapy designation for its investigational programme, SER-155, aimed at decreasing bloodstream infections (BSIs) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results